Alkem Laboratories said that it has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India.
| Subscribe To Our Free Newsletter |
